Patent classifications
C07C57/145
Salt type and crystal type of 4H-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof
Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1,5-alpha]benzimidazole compound and a preparation method and intermediate thereof. The 4H-pyrazolo[1,5-alpha]benzimidazole compound is represented by formula I: ##STR00001##
Salt type and crystal type of 4H-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof
Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1,5-alpha]benzimidazole compound and a preparation method and intermediate thereof. The 4H-pyrazolo[1,5-alpha]benzimidazole compound is represented by formula I: ##STR00001##
Water-soluble unit dose articles made from a combination of different films
The present disclosure relates to water-soluble unit dose articles made from a combination of chemically different water-soluble films and optionally containing compositions that are at least partially enclosed by the water-soluble films in at least one compartment.
Water-soluble unit dose articles made from a combination of different films
The present disclosure relates to water-soluble unit dose articles made from a combination of chemically different water-soluble films and optionally containing compositions that are at least partially enclosed by the water-soluble films in at least one compartment.
Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors
The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.
Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors
The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.
FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
The present application in some embodiments provides a pharmaceutical composition comprising:
##STR00001## and a compounding agent. Further provided herein are methods of making and methods of using the pharmaceutical compositions, for example, in the treatment of cancer.
Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
The invention relates to 5-(((1R,1aS,6bR)-1-(6-(trifluoromethyl)-1H-benzo [d] imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa [b] benzofuran-5-yl) oxy)-3,4-dihydro-1, 8-naphthyridin-2 (1H)-one (Compound 1) maleate salts, in particular the sesqui-maleate salt and its crystalline forms, methods of preparation, pharmaceutical compositions, and therapeutic uses for treatment of diseases or disorders mediated by BRAF or other kinases.
Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
The invention relates to 5-(((1R,1aS,6bR)-1-(6-(trifluoromethyl)-1H-benzo [d] imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa [b] benzofuran-5-yl) oxy)-3,4-dihydro-1, 8-naphthyridin-2 (1H)-one (Compound 1) maleate salts, in particular the sesqui-maleate salt and its crystalline forms, methods of preparation, pharmaceutical compositions, and therapeutic uses for treatment of diseases or disorders mediated by BRAF or other kinases.
Polymorphic forms and co-crystals of a c-Met inhibitor
Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.